Latest News and Press Releases

Want to stay updated on the latest news?

Sign into Reader Account Create Reader Account

May 20, 2026 01:30 ET | Source: Synendos Therapeutics AG

Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder

Synendos Therapeutics Starts Phase 2 Trial in Generalized Anxiety Disorder, marking the first time a SERI molecule is dosed in a patient population
September 24, 2025 01:30 ET | Source: Synendos Therapeutics AG

Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials, Paving the Way for Phase 2 in Mental Health

Synendos Therapeutics Reports Positive and Highly Promising Topline Results from Phase 1 Trials, Paving the Way for Phase 2 in Mental Health
July 15, 2025 01:30 ET | Source: Synendos Therapeutics AG

Topflight Pharma Development Veteran Joins Synendos

Dr. George Garibaldi is named Chief Medical Officer as Synendos transitions from Phase 1 into Phase 2 of its clinical development strategy.